{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T16:25:41Z","timestamp":1792513541063,"version":"4.5.0"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,11,6]],"date-time":"2019-11-06T00:00:00Z","timestamp":1572998400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,11,6]],"date-time":"2019-11-06T00:00:00Z","timestamp":1572998400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100004320","name":"Shiraz University of Medical Sciences","doi-asserted-by":"crossref","award":["13435"],"award-info":[{"award-number":["13435"]}],"id":[{"id":"10.13039\/501100004320","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Microbiol Immunol"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1007\/s00430-019-00640-7","type":"journal-article","created":{"date-parts":[[2019,11,6]],"date-time":"2019-11-06T20:02:47Z","timestamp":1573070567000},"page":"69-79","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":49,"title":["A new multi-epitope peptide vaccine induces immune responses and protection against Leishmania infantum in BALB\/c mice"],"prefix":"10.1007","volume":"209","author":[{"given":"Bahareh","family":"Vakili","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Navid","family":"Nezafat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bijan","family":"Zare","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nasrollah","family":"Erfani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Akbari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Younes","family":"Ghasemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Reza","family":"Rahbar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gholam Reza","family":"Hatam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,11,6]]},"reference":[{"issue":"1","key":"640_CR1","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s13071-017-2028-5","volume":"10","author":"D Steverding","year":"2017","unstructured":"Steverding D (2017) The history of leishmaniasis. Parasite Vector 10(1):82. https:\/\/doi.org\/10.1186\/s13071-017-2028-5","journal-title":"Parasite Vector"},{"key":"640_CR2","doi-asserted-by":"publisher","first-page":"223","DOI":"10.3389\/fmicb.2012.00223","volume":"3","author":"ME Rogers","year":"2012","unstructured":"Rogers ME (2012) The role of leishmania proteophosphoglycans in sand fly transmission and infection of the Mammalian host. Front Microbiol 3:223\u2013223. https:\/\/doi.org\/10.3389\/fmicb.2012.00223","journal-title":"Front Microbiol"},{"issue":"10\u20133","key":"640_CR3","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1016\/j.ijpara.2007.04.003","volume":"37","author":"PA Bates","year":"2007","unstructured":"Bates PA (2007) Transmission of Leishmania metacyclic promastigotes by phlebotomine sand flies. Int J Parasitol 37(10\u20133):1097\u20131106. https:\/\/doi.org\/10.1016\/j.ijpara.2007.04.003","journal-title":"Int J Parasitol"},{"issue":"6","key":"640_CR4","doi-asserted-by":"publisher","first-page":"e1155","DOI":"10.1371\/journal.pntd.0001155","volume":"5","author":"K Kuhls","year":"2011","unstructured":"Kuhls K, Alam MZ, Cupolillo E, Ferreira GEM, Mauricio IL, Oddone R, Feliciangeli MD, Wirth T, Miles MA, Sch\u00f6nian G (2011) Comparative microsatellite typing of new world Leishmania infantum reveals low heterogeneity among populations and its recent old world origin. PLoS Negl Trop Dis 5(6):e1155. https:\/\/doi.org\/10.1371\/journal.pntd.0001155","journal-title":"PLoS Negl Trop Dis"},{"key":"640_CR5","doi-asserted-by":"publisher","first-page":"147","DOI":"10.2147\/CLEP.S44267","volume":"6","author":"PD Ready","year":"2014","unstructured":"Ready PD (2014) Epidemiology of visceral leishmaniasis. J Clin Epidemiol 6:147\u2013154. https:\/\/doi.org\/10.2147\/CLEP.S44267","journal-title":"J Clin Epidemiol"},{"issue":"22","key":"640_CR6","doi-asserted-by":"publisher","first-page":"11305","DOI":"10.1021\/cr500365f","volume":"114","author":"AS Nagle","year":"2014","unstructured":"Nagle AS, Khare S, Kumar AB, Supek F, Buchynskyy A, Mathison CJN, Chennamaneni NK, Pendem N, Buckner FS, Gelb MH, Molteni V (2014) recent developments in drug discovery for Leishmaniasis and human African Trypanosomiasis. Chem Rev 114(22):11305\u201311347. https:\/\/doi.org\/10.1021\/cr500365f","journal-title":"Chem Rev"},{"issue":"1","key":"640_CR7","first-page":"1","volume":"16","author":"A Oryan","year":"2015","unstructured":"Oryan A (2015) Plant-derived compounds in treatment of leishmaniasis. IJVR 16(1):1\u201319","journal-title":"IJVR"},{"key":"640_CR8","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.ijpddr.2012.01.003","volume":"2","author":"LH Freitas-Junior","year":"2012","unstructured":"Freitas-Junior LH, Chatelain E, Kim HA, Siqueira-Neto JL (2012) Visceral leishmaniasis treatment: what do we have, what do we need and how to deliver it? Int J Parasitol 2:11\u201319. https:\/\/doi.org\/10.1016\/j.ijpddr.2012.01.003","journal-title":"Int J Parasitol"},{"issue":"6","key":"640_CR9","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/S1995-7645(12)60084-4","volume":"5","author":"N Singh","year":"2012","unstructured":"Singh N, Kumar M, Singh RK (2012) Leishmaniasis: current status of available drugs and new potential drug targets. Asian Pac J Trop Dis 5(6):485\u2013497. https:\/\/doi.org\/10.1016\/S1995-7645(12)60084-4","journal-title":"Asian Pac J Trop Dis"},{"issue":"3","key":"640_CR10","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.pt.2016.11.003","volume":"33","author":"A Hefnawy","year":"2017","unstructured":"Hefnawy A, Berg M, Dujardin J-C, De Muylder G (2017) Exploiting knowledge on Leishmania drug resistance to support the quest for new drugs. Trends Parasitol 33(3):162\u2013174. https:\/\/doi.org\/10.1016\/j.pt.2016.11.003","journal-title":"Trends Parasitol"},{"issue":"12","key":"640_CR11","doi-asserted-by":"publisher","first-page":"e0006052","DOI":"10.1371\/journal.pntd.0006052","volume":"11","author":"A Ponte-Sucre","year":"2017","unstructured":"Ponte-Sucre A, Gamarro F, Dujardin JC, Barrett MP, Lopez-Velez R, Garcia-Hernandez R, Pountain AW, Mwenechanya R, Papadopoulou B (2017) Drug resistance and treatment failure in leishmaniasis: A 21st century challenge. PLoS Negl Trop Dis 11(12):e0006052. https:\/\/doi.org\/10.1371\/journal.pntd.0006052","journal-title":"PLoS Negl Trop Dis"},{"key":"640_CR12","doi-asserted-by":"publisher","first-page":"892817","DOI":"10.1155\/2012\/892817","volume":"2012","author":"KJ Evans","year":"2012","unstructured":"Evans KJ, Kedzierski L (2012) Development of vaccines against visceral Leishmaniasis. J Trop Med 2012:892817. https:\/\/doi.org\/10.1155\/2012\/892817","journal-title":"J Trop Med"},{"issue":"12","key":"640_CR13","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1590\/S0100-879X2012007500142","volume":"45","author":"IP Nascimento","year":"2012","unstructured":"Nascimento IP, Leite LCC (2012) Recombinant vaccines and the development of new vaccine strategies. Braz J Med Biol Rre 45(12):1102\u20131111. https:\/\/doi.org\/10.1590\/S0100-879X2012007500142","journal-title":"Braz J Med Biol Rre"},{"key":"640_CR14","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.actatropica.2017.04.029","volume":"172","author":"M Akbari","year":"2017","unstructured":"Akbari M, Oryan A, Hatam G (2017) Application of nanotechnology in treatment of leishmaniasis: a review. Acta Trop 172:86\u201390. https:\/\/doi.org\/10.1016\/j.actatropica.2017.04.029","journal-title":"Acta Trop"},{"key":"640_CR15","doi-asserted-by":"publisher","first-page":"25","DOI":"10.2147\/DDDT.S146521","volume":"12","author":"M Ghorbani","year":"2018","unstructured":"Ghorbani M, Farhoudi R (2018) Leishmaniasis in humans: drug or vaccine therapy? Drug Des Dev Ther 12:25\u201340. https:\/\/doi.org\/10.2147\/DDDT.S146521","journal-title":"Drug Des Dev Ther"},{"key":"640_CR16","doi-asserted-by":"publisher","first-page":"465","DOI":"10.3389\/fimmu.2018.00465","volume":"9","author":"A Almeida","year":"2018","unstructured":"Almeida A, Machado LFM, Doro D, Nascimento FC, Damasceno L, Gazzinelli RT, Fernandes AP, Junqueira C (2018) New vaccine formulations containing a modified version of the amastigote 2 antigen and the non-virulent Trypanosoma cruzi CL-14 strain are highly antigenic and protective against Leishmania infantum challenge. Front Immunol 9:465. https:\/\/doi.org\/10.3389\/fimmu.2018.00465","journal-title":"Front Immunol"},{"issue":"12\u201313","key":"640_CR17","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1016\/j.micinf.2010.06.008","volume":"12","author":"MA Ch\u00e1vez-Fumagalli","year":"2010","unstructured":"Ch\u00e1vez-Fumagalli MA, Costa MA, Oliveira DM, Ram\u00edrez L, Costa LE, Duarte MC (2010) Vaccination with the Leishmania infantum ribosomal proteins induces protection in BALB\/c mice against Leishmania chagasi and Leishmania amazonensis challenge. Microbes Infect 12(12\u201313):967\u2013977. https:\/\/doi.org\/10.1016\/j.micinf.2010.06.008","journal-title":"Microbes Infect"},{"issue":"9","key":"640_CR18","doi-asserted-by":"publisher","first-page":"4648","DOI":"10.1128\/IAI.00394-07","volume":"75","author":"RN Coler","year":"2007","unstructured":"Coler RN, Goto Y, Bogatzki L, Raman V, Reed SG (2007) Leish-111f, a recombinant polyprotein vaccine that protects against visceral Leishmaniasis by elicitation of CD4\u2009+\u2009T cells. Infect Immun 75:(9)4648\u20134654. https:\/\/doi.org\/10.1128\/IAI.00394-07","journal-title":"Infect Immun"},{"issue":"1","key":"640_CR19","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1186\/s13071-016-1412-x","volume":"9","author":"V Rodrigues","year":"2016","unstructured":"Rodrigues V, Cordeiro-Da-Silva A, Laforge M, Silvestre R, Estaquier J (2016) Regulation of immunity during visceral Leishmania infection. Parasite Vector 9(1):118. https:\/\/doi.org\/10.1186\/s13071-016-1412-x","journal-title":"Parasite Vector"},{"issue":"7","key":"640_CR20","doi-asserted-by":"publisher","first-page":"901","DOI":"10.2217\/fmb.14.43","volume":"9","author":"F Khadem","year":"2014","unstructured":"Khadem F, Uzonna JE (2014) Immunity to visceral leishmaniasis: implications for immunotherapy. Future Microbiol 9(7):901\u2013915. https:\/\/doi.org\/10.2217\/fmb.14.43","journal-title":"Future Microbiol"},{"issue":"6","key":"640_CR21","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1111\/sji.12175","volume":"79","author":"PA Bretscher","year":"2014","unstructured":"Bretscher PA (2014) On the mechanism determining the Th1\/Th2 phenotype of an immune response, and its pertinence to strategies for the prevention, and treatment, of certain infectious diseases. Scand J Immunol 79(6):361\u2013376. https:\/\/doi.org\/10.1111\/sji.12175","journal-title":"Scand J Immunol"},{"issue":"1","key":"640_CR22","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1186\/s13071-016-1777-x","volume":"9","author":"SCF Mendon\u00e7a","year":"2016","unstructured":"Mendon\u00e7a SCF (2016) Differences in immune responses against Leishmania induced by infection and by immunization with killed parasite antigen: implications for vaccine discovery. Parasite Vector 9(1):492. https:\/\/doi.org\/10.1186\/s13071-016-1777-x","journal-title":"Parasite Vector"},{"issue":"4","key":"640_CR23","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1039\/c6mb00772d","volume":"13","author":"N Nezafat","year":"2017","unstructured":"Nezafat N, Eslami M, Negahdaripour M, Rahbar MR, Ghasemi Y (2017) Designing an efficient multi-epitope oral vaccine against Helicobacter pylori using immunoinformatics and structural vaccinology approaches. Mol BioSyst 13(4):699\u2013713. https:\/\/doi.org\/10.1039\/c6mb00772d","journal-title":"Mol BioSyst"},{"key":"640_CR24","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.molimm.2018.11.005","volume":"104","author":"M Validi","year":"2018","unstructured":"Validi M, Karkhah A, Prajapati VK, Nouri HR (2018) Immuno-informatics based approaches to design a novel multi epitope-based vaccine for immune response reinforcement against Leptospirosis. Mol Immunol 104:128\u2013138. https:\/\/doi.org\/10.1016\/j.molimm.2018.11.005","journal-title":"Mol Immunol"},{"issue":"2013","key":"640_CR25","doi-asserted-by":"publisher","first-page":"601943","DOI":"10.1155\/2013\/601943","volume":"2013","author":"M Molero-Abraham","year":"2013","unstructured":"Molero-Abraham M, Lafuente EM, Flower DR, Reche PA (2013) Selection of conserved epitopes from hepatitis C virus for pan-populational stimulation of T-cell responses. Clin Dev Immunol 2013(2013):601943. https:\/\/doi.org\/10.1155\/2013\/601943","journal-title":"Clin Dev Immunol"},{"issue":"1","key":"640_CR26","doi-asserted-by":"publisher","first-page":"9044","DOI":"10.1038\/s41598-018-26689-7","volume":"8","author":"V Solanki","year":"2018","unstructured":"Solanki V, Tiwari V (2018) Subtractive proteomics to identify novel drug targets and reverse vaccinology for the development of chimeric vaccine against Acinetobacter baumannii. Sci Rep 8(1):9044. https:\/\/doi.org\/10.1038\/s41598-018-26689-7","journal-title":"Sci Rep"},{"key":"640_CR27","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1016\/j.ijbiomac.2018.08.125","volume":"120","author":"B Vakili","year":"2018","unstructured":"Vakili B, Eslami M, Hatam GR, Zare B, Erfani N, Nezafat N, Ghasemi Y (2018) Immunoinformatics-aided design of a potential multi-epitope peptide vaccine against Leishmania infantum. Int J Biol Macromol 120:1127\u20131139. https:\/\/doi.org\/10.1016\/j.ijbiomac.2018.08.125","journal-title":"Int J Biol Macromol"},{"key":"640_CR28","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.compbiolchem.2017.12.008","volume":"72","author":"B Vakili","year":"2018","unstructured":"Vakili B, Nezafat N, Hatam GR, Zare B, Erfani N, Ghasemi Y (2018) Proteome-scale identification of Leishmania infantum for novel vaccine candidates: a hierarchical subtractive approach. Comput Biol Chem 72:16\u201325. https:\/\/doi.org\/10.1016\/j.compbiolchem.2017.12.008","journal-title":"Comput Biol Chem"},{"issue":"1","key":"640_CR29","doi-asserted-by":"publisher","first-page":"e0005311","DOI":"10.1371\/journal.pntd.0005311","volume":"11","author":"M Agallou","year":"2017","unstructured":"Agallou M, Margaroni M, Athanasiou E, Toubanaki DK, Kontonikola K, Karidi K, Kammona O, Kiparissides C, Karagouni E (2017) Identification of BALB\/c immune markers correlated with a partial protection to Leishmania infantum after vaccination with a rationally designed multi-epitope cysteine protease a peptide-based nanovaccine. PLoS Negl Trop Dis 11(1):e0005311. https:\/\/doi.org\/10.1371\/journal.pntd.0005311","journal-title":"PLoS Negl Trop Dis"},{"issue":"2","key":"640_CR30","first-page":"75","volume":"60","author":"S Dasgupta","year":"2014","unstructured":"Dasgupta S, Aghazadeh-Dibavar S, Bandyopadyay M (2014) The role of toll-like receptor agonists in the immunotherapy of leishmaniosis. An update and proposal for a new form of anti-leishmanial therapy. Ann Parasitol 60(2):75\u201382","journal-title":"Ann Parasitol"},{"issue":"1","key":"640_CR31","doi-asserted-by":"publisher","first-page":"6957","DOI":"10.1038\/s41598-018-25374-z","volume":"8","author":"VS Aathmanathan","year":"2018","unstructured":"Aathmanathan VS, Jothi N, Prajapati VK, Krishnan M (2018) Investigation of immunogenic properties of Hemolin from silkworm, Bombyx mori as carrier protein: an immunoinformatic approach. Sci Rep 8(1):6957. https:\/\/doi.org\/10.1038\/s41598-018-25374-z","journal-title":"Sci Rep"},{"issue":"1","key":"640_CR32","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1586\/14760584.2016.1105135","volume":"15","author":"SG Reed","year":"2016","unstructured":"Reed SG, Coler RN, Mondal D, Kamhawi S, Valenzuela JG (2016) Leishmania vaccine development: exploiting the host-vector-parasite interface. Expert Rev Vaccines 15(1):81\u201390. https:\/\/doi.org\/10.1586\/14760584.2016.1105135","journal-title":"Expert Rev Vaccines"},{"issue":"1043","key":"640_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2018.01043","volume":"9","author":"RCF De Brito","year":"2018","unstructured":"De Brito RCF, Cardoso JMDO, Reis LES, Vieira JF, Mathias FAS, Roatt BM, Aguiar-Soares RDDO, Ruiz JC, Resende DDM, Reis AB (2018) Peptide vaccines for Leishmaniasis. Front Immunol 9(1043):1\u201311. https:\/\/doi.org\/10.3389\/fimmu.2018.01043","journal-title":"Front Immunol"},{"key":"640_CR34","doi-asserted-by":"publisher","first-page":"884","DOI":"10.3389\/fimmu.2018.00884","volume":"9","author":"BJ Hos","year":"2018","unstructured":"Hos BJ, Tondini E, Van Kasteren SI, Ossendorp F (2018) Approaches to improve chemically defined synthetic peptide vaccines. Front Immunol 9:884\u2013884. https:\/\/doi.org\/10.3389\/fimmu.2018.00884","journal-title":"Front Immunol"},{"issue":"11","key":"640_CR35","doi-asserted-by":"publisher","first-page":"e1003001","DOI":"10.1371\/journal.ppat.1003001","volume":"8","author":"C Rueckert","year":"2012","unstructured":"Rueckert C, Guzm\u00e1n CA (2012) Vaccines: from empirical development to rational design. PLoS Pathog 8(11):e1003001. https:\/\/doi.org\/10.1371\/journal.ppat.1003001","journal-title":"PLoS Pathog"},{"issue":"42","key":"640_CR36","doi-asserted-by":"publisher","first-page":"7450","DOI":"10.1016\/j.vaccine.2007.08.001","volume":"25","author":"Y Goto","year":"2007","unstructured":"Goto Y, Bogatzki LY, Bertholet S, Coler RN, Reed SG (2007) Protective immunization against visceral leishmaniasis using Leishmania sterol 24-c-methyltransferase formulated in adjuvant. Vaccine 25(42):7450\u20137458. https:\/\/doi.org\/10.1016\/j.vaccine.2007.08.001","journal-title":"Vaccine"},{"issue":"3","key":"640_CR37","doi-asserted-by":"publisher","first-page":"515","DOI":"10.3390\/vaccines2030515","volume":"2","author":"W Li","year":"2014","unstructured":"Li W, Joshi MD, Singhania S, Ramsey KH, Murthy AK (2014) Peptide vaccine: progress and challenges. Vaccines 2(3):515\u2013536. https:\/\/doi.org\/10.3390\/vaccines2030515","journal-title":"Vaccines"},{"issue":"7","key":"640_CR38","doi-asserted-by":"publisher","first-page":"3988","DOI":"10.1128\/iai.71.7.3988-3994.2003","volume":"71","author":"EA Coelho","year":"2003","unstructured":"Coelho EA, Tavares CAP, Carvalho FAA, Chaves KF, Teixeira KN, Rodrigues RC (2003) Immune responses induced by the Leishmania (Leishmania) donovani A2 antigen, but not by the LACK antigen, are protective against experimental Leishmania (Leishmania) amazonensis infection. Infect Immun 71(7):3988\u20133994. https:\/\/doi.org\/10.1128\/iai.71.7.3988-3994.2003","journal-title":"Infect Immun"},{"issue":"1","key":"640_CR39","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.vaccine.2009.09","volume":"28","author":"A Mizbani","year":"2009","unstructured":"Mizbani A, Taheri T, Zahedifard F, Taslimi Y, Azizi H, Azadmanesh K, Papadopoulou B, Rafati S (2009) Recombinant Leishmania tarentolae expressing the A2 virulence gene as a novel candidate vaccine against visceral leishmaniasis. Vaccine 28(1):53\u201362. https:\/\/doi.org\/10.1016\/j.vaccine.2009.09","journal-title":"Vaccine"},{"issue":"35","key":"640_CR40","doi-asserted-by":"publisher","first-page":"4585","DOI":"10.1016\/j.vaccine.2008.05.091","volume":"26","author":"DM Resende","year":"2008","unstructured":"Resende DM, Caetano BC, Dutra MS, Penido ML, Abrantes CF, Verly RM, Resende JM, Pil\u00f3-Veloso D, Rezende SA, Bruna-Romero O (2008) Epitope mapping and protective immunity elicited by adenovirus expressing the Leishmania amastigote specific A2 antigen: correlation with IFN-\u03b3 and cytolytic activity by CD8+\u2009T cells. Vaccine 26(35):4585\u20134593. https:\/\/doi.org\/10.1016\/j.vaccine.2008.05.091","journal-title":"Vaccine"},{"issue":"19","key":"640_CR41","doi-asserted-by":"publisher","first-page":"2233","DOI":"10.1016\/j.vaccine.2016.03.019","volume":"34","author":"S Regina-Silva","year":"2016","unstructured":"Regina-Silva S, Feres AMLT, Fran\u00e7a-Silva JC, Dias ES, Michalsky \u00c9M, De Andrade HM, Coelho EAF, Ribeiro GM, Fernandes AP, Machado-Coelho GLL (2016) Field randomized trial to evaluate the efficacy of the Leish-Tec\u00ae vaccine against canine visceral leishmaniasis in an endemic area of Brazil. Vaccine 34(19):2233\u20132239. https:\/\/doi.org\/10.1016\/j.vaccine.2016.03.019","journal-title":"Vaccine"},{"issue":"5","key":"640_CR42","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1128\/CDLI.4.5.530-535.1997","volume":"4","author":"E Ghedin","year":"1997","unstructured":"Ghedin E, Zhang WW, Charest H, Sundar S, Kenney RT, Matlashewski G (1997) Antibody response against a Leishmania donovani amastigote-stage-specific protein in patients with visceral leishmaniasis. Clin Diagn Lab Immunol 4(5):530\u2013535","journal-title":"Clin Diagn Lab Immunol"},{"issue":"2","key":"640_CR43","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/S0166-6851(99)00098-5","volume":"102","author":"A Bhatia","year":"1999","unstructured":"Bhatia A, Daifalla NS, Jen S, Badaro R, Reed SG, Skeiky YA (1999) Cloning, characterization and serological evaluation of K9 and K26: two related hydrophilic antigens of Leishmania chagasi. Mol Biochem Parasitol 102(2):249\u2013261","journal-title":"Mol Biochem Parasitol"},{"key":"640_CR44","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.3389\/fimmu.2018.01360","volume":"9","author":"DG Doherty","year":"2018","unstructured":"Doherty DG, Melo AM, Moreno-Olivera A, Solomos AC (2018) Activation and regulation of B cell responses by invariant natural killer T Cells. Front Immunol 9:1360. https:\/\/doi.org\/10.3389\/fimmu.2018.01360","journal-title":"Front Immunol"},{"issue":"3","key":"640_CR45","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1111\/j.1365-2567.2007.02719.x","volume":"123","author":"GE Kaiko","year":"2008","unstructured":"Kaiko GE, Horvat JC, Beagley KW, Hansbro PM (2008) Immunological decision-making: how does the immune system decide to mount a helper T-cell response? Immunology 123(3):326\u2013338. https:\/\/doi.org\/10.1111\/j.1365-2567.2007.02719.x","journal-title":"Immunology"},{"key":"640_CR46","doi-asserted-by":"publisher","first-page":"80","DOI":"10.3389\/fimmu.2012.00080","volume":"3","author":"J Alexander","year":"2012","unstructured":"Alexander J, Brombacher F (2012) T helper1\/t helper2 cells and resistance\/susceptibility to leishmania infection: is this paradigm still relevant? Front Immunol 3:80\u201380. https:\/\/doi.org\/10.3389\/fimmu.2012.00080","journal-title":"Front Immunol"},{"issue":"9","key":"640_CR47","doi-asserted-by":"publisher","first-page":"5842","DOI":"10.1128\/IAI.73.9.5842-5852.2005","volume":"73","author":"S Iborra","year":"2005","unstructured":"Iborra S, Carri\u00f3n J, Anderson C, Alonso C, Sacks D, Soto M (2005) Vaccination with the Leishmania infantum acidic ribosomal P0 protein plus CpG oligodeoxynucleotides induces protection against cutaneous leishmaniasis in C57BL\/6 mice but does not prevent progressive disease in BALB\/c mice. Infect Immun 73(9):5842\u20135852. https:\/\/doi.org\/10.1128\/IAI.73.9.5842-5852.2005","journal-title":"Infect Immun"},{"issue":"1","key":"640_CR48","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1186\/s13071-016-1598-y","volume":"9","author":"L Solano-Gallego","year":"2016","unstructured":"Solano-Gallego L, Montserrat-Sangr\u00e0 S, Ordeix L, Mart\u00ednez-Orellana P (2016) Leishmania infantum-specific production of IFN-\u03b3 and IL-10 in stimulated blood from dogs with clinical leishmaniosis. Parasite Vector 9(1):317. https:\/\/doi.org\/10.1186\/s13071-016-1598-y","journal-title":"Parasite Vector"},{"issue":"4","key":"640_CR49","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1084\/jem.179.4.1367","volume":"179","author":"Z-E Wang","year":"1994","unstructured":"Wang Z-E, Reiner SL, Zheng S, Dalton DK, Locksley RM (1994) CD4+ effector cells default to the Th2 pathway in interferon gamma-deficient mice infected with Leishmania major. J Exp Med 179(4):1367\u20131371","journal-title":"J Exp Med"},{"issue":"7","key":"640_CR50","doi-asserted-by":"publisher","first-page":"187","DOI":"10.3389\/fimmu.2016.00187","volume":"13","author":"S Gannavaram","year":"2016","unstructured":"Gannavaram S, Bhattacharya P, Ismail N, Kaul A, Singh R, Nakhasi HL (2016) Modulation of innate immune mechanisms to enhance Leishmania vaccine-induced immunity: role of coinhibitory molecules. Front Immunol 13(7):187. https:\/\/doi.org\/10.3389\/fimmu.2016.00187","journal-title":"Front Immunol"},{"key":"640_CR51","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/B978-0-12-407679-2.00005-3","volume":"82","author":"G Gupta","year":"2013","unstructured":"Gupta G, Oghumu S, Satoskar AR (2013) Mechanisms of immune evasion in leishmaniasis. Adv Appl Microbiol 82:155\u2013184. https:\/\/doi.org\/10.1016\/B978-0-12-407679-2.00005-3","journal-title":"Adv Appl Microbiol"},{"issue":"4","key":"640_CR52","first-page":"570","volume":"69","author":"F Liew","year":"1990","unstructured":"Liew F, Parkinson C, Millott S, Severn A, Carrier M (1990) Tumour necrosis factor (TNF alpha) in leishmaniasis. I. TNF alpha mediates host protection against cutaneous leishmaniasis. Immunology 69(4):570","journal-title":"Immunology"},{"issue":"8","key":"640_CR53","doi-asserted-by":"crossref","first-page":"3949","DOI":"10.4049\/jimmunol.160.8.3949","volume":"160","author":"A Sj\u00f6lander","year":"1998","unstructured":"Sj\u00f6lander A, Baldwin TM, Curtis JM, Handman E (1998) Induction of a Th1 immune response and simultaneous lack of activation of a Th2 response are required for generation of immunity to leishmaniasis. J Immunol 160(8):3949\u20133957","journal-title":"J Immunol"},{"issue":"11","key":"640_CR54","doi-asserted-by":"publisher","first-page":"7160","DOI":"10.4049\/jimmunol.174.11.7160","volume":"174","author":"R Basu","year":"2005","unstructured":"Basu R, Bhaumik S, Basu JM, Naskar K, De T, Roy S (2005) Kinetoplastid membrane protein-11 DNA vaccination induces complete protection against both pentavalent antimonial-sensitive and-resistant strains of Leishmania donovani that correlates with inducible nitric oxide synthase activity and IL-4 generation: evidence for mixed Th1-and Th2-like responses in visceral leishmaniasis. J Immunol 174(11):7160\u20137171. https:\/\/doi.org\/10.4049\/jimmunol.174.11.7160","journal-title":"J Immunol"},{"issue":"11","key":"640_CR55","doi-asserted-by":"publisher","first-page":"7620","DOI":"10.1128\/IAI.73.11.7620-7628.2005","volume":"73","author":"MT Roberts","year":"2005","unstructured":"Roberts MT, Stober CB, Mckenzie AN, Blackwell JM (2005) Interleukin-4 (IL-4) and IL-10 collude in vaccine failure for novel exacerbatory antigens in murine Leishmania major infection. Infect Immun 73(11):7620\u20137628","journal-title":"Infect Immun"},{"issue":"2","key":"640_CR56","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.imlet.2013.12.022","volume":"161","author":"R Hurdayal","year":"2014","unstructured":"Hurdayal R, Brombacher F (2014) The role of IL-4 and IL-13 in cutaneous Leishmaniasis. Immunol Lett 161(2):179\u2013183. https:\/\/doi.org\/10.1016\/j.imlet.2013.12.022","journal-title":"Immunol Lett"},{"issue":"10","key":"640_CR57","doi-asserted-by":"publisher","first-page":"2848","DOI":"10.1002\/1521-4141(2001010)31:10<2848::AID-IMMU2848>3.0.CO;2-T","volume":"31","author":"ML Murphy","year":"2001","unstructured":"Murphy ML, Wille U, Villegas EN, Hunter CA, Farrell JP (2001) IL-10 mediates susceptibility to Leishmania donovani infection. Eur J Immunol 31(10):2848\u20132856","journal-title":"Eur J Immunol"},{"issue":"12","key":"640_CR58","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1038\/ni1539","volume":"8","author":"MJ Mcgeachy","year":"2007","unstructured":"Mcgeachy MJ, Bak-Jensen KS, Chen Y, Tato CM, Blumenschein W, Mcclanahan T, Cua DJ (2007) TGF-beta and IL-6 drive the production of IL-17 and IL-10 by T cells and restrain T(H)-17 cell-mediated pathology. Nat Immunol 8(12):1390\u20131397. https:\/\/doi.org\/10.1038\/ni1539","journal-title":"Nat Immunol"},{"issue":"11","key":"640_CR59","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1038\/ni725","volume":"2","author":"T Biedermann","year":"2001","unstructured":"Biedermann T, Zimmermann S, Himmelrich H, Gumy A, Egeter O, Sakrauski AK, Seegmuller I, Voigt H, Launois P, Levine AD, Wagner H, Heeg K, Louis JA, Rocken M (2001) IL-4 instructs TH1 responses and resistance to Leishmania major in susceptible BALB\/c mice. Nat Immunol 2(11):1054\u20131060. https:\/\/doi.org\/10.1038\/ni725","journal-title":"Nat Immunol"},{"issue":"4","key":"640_CR60","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1002\/eji.1830270409","volume":"27","author":"I Vouldoukis","year":"1997","unstructured":"Vouldoukis I, Becherel PA, Riveros-Moreno V, Arock M, Da Silva O, Debre P, Mazier D, Mossalayi MD (1997) Interleukin-10 and interleukin-4 inhibit intracellular killing of Leishmania infantum and Leishmania major by human macrophages by decreasing nitric oxide generation. Eur J Immunol 27(4):860\u2013865. https:\/\/doi.org\/10.1002\/eji.1830270409","journal-title":"Eur J Immunol"},{"issue":"2","key":"640_CR61","doi-asserted-by":"publisher","first-page":"135","DOI":"10.4103\/0974-777X.62876","volume":"2","author":"S Nyl\u00e9n","year":"2010","unstructured":"Nyl\u00e9n S, Gautam S (2010) Immunological perspectives of leishmaniasis. J Glob Infect Dis 2(2):135\u2013146. https:\/\/doi.org\/10.4103\/0974-777X.62876","journal-title":"J Glob Infect Dis"},{"issue":"1\u20132","key":"640_CR62","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/S0264-410X(01)00322-X","volume":"20","author":"A Ghosh","year":"2001","unstructured":"Ghosh A, Zhang WW, Matlashewski G (2001) Immunization with A2 protein results in a mixed Th1\/Th2 and a humoral response which protects mice against Leishmania donovani infections. Vaccine 20(1\u20132):59\u201366","journal-title":"Vaccine"},{"issue":"28","key":"640_CR63","doi-asserted-by":"publisher","first-page":"3716","DOI":"10.1016\/j.vaccine.2005.02.009","volume":"23","author":"H Darabi","year":"2005","unstructured":"Darabi H, Eravani D, Sanos S, Kaye P, Taghikhani M, Jamshidi S (2005) Protective vaccination against experimental canine visceral leishmaniasis using a combination of DNA and protein immunization with cysteine proteinases type I and II of L. infantum. Vaccine 23(28):3716\u20133725","journal-title":"Vaccine"},{"issue":"12","key":"640_CR64","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1016\/j.vaccine.2005.11.011","volume":"24","author":"S Rafati","year":"2006","unstructured":"Rafati S, Zahedifard F, Nazgouee F (2006) Prime-boost vaccination using cysteine proteinases type I and II of Leishmania infantum confers protective immunity in murine visceral leishmaniasis. Vaccine 24(12):2169\u20132175","journal-title":"Vaccine"},{"issue":"1","key":"640_CR65","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/S1674-8301(10)60004-8","volume":"24","author":"JM Mutiso","year":"2010","unstructured":"Mutiso JM, Macharia JC, Gicheru MM (2010) A review of adjuvants for Leishmania vaccine candidates. Biomed Res 24(1):16\u201325. https:\/\/doi.org\/10.1016\/S1674-8301(10)60004-8","journal-title":"Biomed Res"},{"issue":"4","key":"640_CR66","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1097\/PPO.0b013e3181eaca65","volume":"16","author":"S Gnjatic","year":"2010","unstructured":"Gnjatic S, Sawhney NB, Bhardwaj N (2010) Toll-like receptor agonists: are they good adjuvants? Cancer J (Sudbury, Mass) 16(4):382\u2013391. https:\/\/doi.org\/10.1097\/PPO.0b013e3181eaca65","journal-title":"Cancer J (Sudbury, Mass)"},{"key":"640_CR67","doi-asserted-by":"publisher","DOI":"10.3390\/molecules23071583","author":"Q Li","year":"2018","unstructured":"Li Q, Guo Z (2018) Recent advances in toll like receptor-targeting glycoconjugate vaccines. Molecules. https:\/\/doi.org\/10.3390\/molecules23071583","journal-title":"Molecules"},{"key":"640_CR68","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.coi.2016.06.007","volume":"41","author":"SG Reed","year":"2016","unstructured":"Reed SG, Hsu F-C, Carter D, Orr MT (2016) The science of vaccine adjuvants: advances in TLR4 ligand adjuvants. Curr Opin Immunol 41:85\u201390","journal-title":"Curr Opin Immunol"},{"issue":"4","key":"640_CR69","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1189\/jlb.0912435","volume":"94","author":"JS Kim","year":"2013","unstructured":"Kim JS, Kim WS, Choi HG, Jang B, Lee K, Park JH, Kim HJ, Cho SN, Shin SJ (2013) Mycobacterium tuberculosis RpfB drives Th1-type T cell immunity via a TLR4-dependent activation of dendritic cells. J Leukoc Biol 94(4):733\u2013749. https:\/\/doi.org\/10.1189\/jlb.0912435","journal-title":"J Leukoc Biol"},{"issue":"7","key":"640_CR70","doi-asserted-by":"publisher","first-page":"1957","DOI":"10.1002\/eji.201445329","volume":"45","author":"HG Choi","year":"2015","unstructured":"Choi HG, Kim WS, Back YW, Kim H, Kwon KW, Kim JS, Shin SJ, Kim HJ (2015) Mycobacterium tuberculosis RpfE promotes simultaneous Th1- and Th17-type T-cell immunity via TLR4-dependent maturation of dendritic cells. Eur J Immunol 45(7):1957\u20131971. https:\/\/doi.org\/10.1002\/eji.201445329","journal-title":"Eur J Immunol"}],"container-title":["Medical Microbiology and Immunology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00430-019-00640-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00430-019-00640-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00430-019-00640-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,22]],"date-time":"2023-09-22T15:25:57Z","timestamp":1695396357000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00430-019-00640-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,6]]},"references-count":70,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["640"],"URL":"https:\/\/doi.org\/10.1007\/s00430-019-00640-7","relation":{},"ISSN":["0300-8584","1432-1831"],"issn-type":[{"value":"0300-8584","type":"print"},{"value":"1432-1831","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,6]]},"assertion":[{"value":"3 May 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 November 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All applicable international, national, and\/or institutional guidelines for the care and use of animals were followed.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}